Toronto, December 30, 2020 (GLOBE NEWSWIRE) — RAMM Pharma Corp. (wholly owned subsidiary, including “Company” or “RAMM”) (CSE: RAMM), a leader in plant-derived cannabinoid drugs and other cannabis-based Our products are Canapar Corp. We are pleased to inform you that we have acquired 49% (“Canapar shares”) of (“Canapar”). Canapar shares were acquired from Canopy Rivers Corporation (“Canopy Rivers”), a wholly owned subsidiary of Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF). Fully operational through its wholly owned subsidiary, Canapar SrL (“Canapar Italy”), Canapar will become one of Europe’s largest vertically integrated cannabis companies. Canapar’s state-of-the-art extraction plant is Europe’s largest, customizing 1,000 hectares of Italy-based organic hemp production and processing platforms for the production of active compounds used in high-quality pharmaceuticals, wellness and cosmetics. It is designed. .. Strategic investments will immediately strengthen RAMM’s and Canapar’s ability to leverage the rapidly expanding European and global cannabis markets, with RAMM’s portfolio of internationally registered and approved pharmaceuticals and other cannabis-based products. It is expected to provide and leverage additional opportunities to expand the distribution footprint. Canapar’s significant investment in a wide range of vertically integrated operations and industry expertise.
Jack Burnett, RAMM’s Chief Executive Officer, said:Sergio Martines, Canapar’s Chief Executive Officer, said: “We welcome RAMM as a strategic investor in Canapar and are very optimistic about the opportunity to reciprocate their respective expertise, product portfolio and established presence in the vast number of international markets.Watch a video outlining Canapar’s operations here Additional information about Canapar can be found on its website. www.canapar.com..About the European cannabis marketEurope is one of the largest potential cannabis markets in the world. The European cannabis market is currently valued at US $ 3.5 billion, with a CAGR of 29.6% from 2020 to 2027 and expected to reach US $ 37 billion by 2027 (ResearchAndMarkets.com, 2020). ). European countries are undergoing regulatory changes in the sale of cannabis and related products, facilitating easier cultivation, processing, and trading of cannabis-derived products throughout the region.Transaction termsCanapar shares are acquired for C $ 7,000,000 subject to the terms of the Share Purchase Agreement (“Agreement”) and represent approximately 49% of Canapar’s outstanding shares on an undiluted basis. Canopy Rivers will also, at RAMM’s sole discretion, pay in cash or issue C $ 2,000,000 in RAMM’s common stock for achieving certain production milestones at the Canapal Italia production facility in Sicily. You are entitled to additional incidental consideration. Subject to the terms of the agreement, RAMM has also been assigned Canopy Rivers rights under an Investor Rights Agreement, including: (I) Right to appoint one candidate to Kanapar’s current three boards (or the board will increase to six or more); (ii) Kanapar’s in connection with future financing Ram’s right to maintain a proportional ownership ratio. (Iii) A call option that provides RAMM with the right to purchase 100% of Canapar’s stake in the investee company at a value of C $ 200 million or eight times EBITDA.
About Canapar CorpWith a wholly owned subsidiary in Europe, Canapar is an Italian-based manufacturer and processor of CBD oils and isolates, which is increasingly being used as an input to new products in the health and wellness industry. Canapar has secured over 1,000 hectares of cannabis through an outsourced agricultural model and has entered into an academic partnership with the Faculty of Agriculture at the University of Catania. Canapar is also improving its extraction and processing capacity for CBD through a new facility, converting 600 metric tonnes of hemp biomass annually into CBD isolates and derivatives for distribution in Europe, following a commissioning of the extraction machine. It’s a schedule. Due to the significant increase in demand for products containing naturally active ingredients derived from plant extracts, Canapar has injected CBD into cosmetics, skin care and beauty products for the Italian cosmetics market, which is the fourth largest market in Europe. I am planning to develop. A global market that provides strong demand for the “Made in Italy” brand.RAMM Pharma Corp.aboutLed by renowned cannabis industry experts and backed by a successful pioneer in the cannabis sector, RAMM is a leader in cannabinoid pharmacology and product formulation of cannabis-based medicines and other cannabis-based products. Founded in Montevideo, Uruguay in 1988, the company is a well-established pharmaceutical and medical product business that has developed medically registered and approved plant-derived cannabinoid drugs. We currently have multiple approved and registered products approved for sale in Uruguay and compassionate use in several Latin American countries, as well as a variety of approved and developed products manufactured by our state-of-the-art Good. We have a new product pipeline in the stage. A manufacturing practice (GMP) certified cannabis compounding facility. In addition to its industry-leading activities in the cannabis sector, we have successfully developed pharmaceutical, cosmetics and dietary supplements and medical services businesses that have served the local market for 30 years.RAMM Pharma Corp. has wholly owned subsidiaries Medic Plast SA, Yulelan SA, Glediser SA, and Ramm Pharma Holdings Corp. It is included.Additional information about us is available at the following URL: www.rammpharma.com..For more information, please contact:Jack Burnett
Chief executive officer
+598 2513 9958
[email protected]Precautions regarding future prospectsThis news release includes “forward-looking information” and “forward-looking statements” (collectively, “forward-looking statements”.Description of future prospects“) Within the meaning of applicable Canadian securities law. All statements, except historical facts, are forward-looking statements and are based on expectations, estimates and projections as of the date of this news release. All statements (often “expect”, “not expect”, “expected”, etc., including discussions about forecasts, expectations, beliefs, plans, forecasts, objectives, assumptions, future events or performance. (I use the phrase, but not always), “anticipate” or “unexpected”, “plan”, “budget”, “plan”, “estimate”, “estimate”, “believe” Or “intended” or a variation of such a word or phrase, or an event or result that states “possible” or “possible”, “possible”, “possible” “Yes” or “possible” or “achieved”) may be a statement of future prospects rather than a statement of historical facts. In this news release, forward-looking statements relate specifically to our strategy and objectives and future expansion plans.These forward-looking statements are based on reasonable assumptions and estimates by our management at the time such statements were made. Forward-looking statements include known and unknown risks, uncertainties, and other factors, so actual future results may vary significantly. A description of the future outlook. Such factors include, among others: Expected profit from the acquisition of Kanapar shares for the Company and its shareholders.Our future growth potential after the acquisitionTest run of Canapar Italy extractor. The effectiveness of our product offerings. Expected timeline related to the production, deployment and availability of our products. Ability to respond to increasing demand for our products and changes in the prices of the products we need. What impact does COVID-19 have on our workforce, suppliers, partners, customers, and other critical resources, and what impact will it have on our business and operations if they occur? Potential for our future growth; Fluctuations in general macroeconomic conditions; Fluctuations in the stock market; Expectations for changes in the size and consumer habits of the Uruguay, Latin American, European and international medical and recreational cannabis markets. The ability of a company to successfully achieve its business goals. Plans for expansion; Political and social uncertainties; Insufficient insurance to cover risks and hazards. Existence of laws and regulations that may impose restrictions on the cultivation, production, distribution and sale of Uruguay or international cannabis and cannabis-related products. And employee relationships. The forward-looking statements contained in this news release are based on what our management believes to be, or at that time, reasonable assumptions, but the actual results are such. We cannot guarantee to shareholders that it is consistent with the forward-looking statements. There may be other factors that may cause the results to be unpredictable, estimated, or not what you intended. Readers should not place undue reliance on any forward-looking statements or information contained in this news release. We undertake no obligation to update any changes in our beliefs, opinions, forecasts or other factors regarding our outlook, except as required by law.The stock exchange, securities committee, or other regulator has not endorsed or dismissed the information contained herein.
CBJ News Maker
RAMM Pharma has entered the European cannabis market with strategic investments in Canadian Corp. and the Canadian Business Journal.